Which Pharma - API Stocks Are Deep Value Picks in Week of May 10, 2026?

Sector Pulse

The Pharma - API sector demonstrated an IMPROVING demand environment this quarter, with 3 of 4 constituents reporting positive momentum. However, performance was polarized. SENORES delivered a 64% YoY revenue increase to INR 175 crores, while 506414 saw revenue contract 11% YoY to INR 140.5 crore due to a high base effect. Across the board, companies are focusing on margin expansion over pure top-line growth, utilizing cost rationalization to drive profitability.

Catalysts Playing Out Across the Pack

The dominant theme across the sector is Operating Leverage Inflection. All 4 constituents reported active margin expansion. INDSWFTLAB expanded its Operating EBITDA margin by 48 BPS QoQ to 5.95%, citing lower raw material and employee costs. SENORES improved its EBITDA margin by 360 bps YoY to 30.9%. Additionally, Value Added Product Mix Shift is actively playing out for 3 constituents. THEMISMED noted that its API business more than doubled YoY, which helped improve its EBITDA margin by 178 bps to 10.87%, offsetting sluggishness in formulations. Geographical Expansion is also yielding results, with SENORES reporting a 60.5% YoY growth in regulated markets.

What Managements Are Guiding

Forward guidance reflects a CONFIDENT tone, though numeric disclosures were limited. SENORES raised its FY26 profitability guidance to "Better than 100% PAT growth" and expects a minimum of 25% revenue growth for FY27. INDSWFTLAB reaffirmed its target to double revenue by FY29, aiming for a 20-25% topline CAGR and an EBITDA margin expansion of 250-300 BPS. THEMISMED and 506414 refrained from providing specific numeric forward revenue guidance, though 506414 pointed to a 25% YoY growth trajectory over the first nine months as evidence of structural momentum.

Shared Risks (9-type taxonomy)

The sector faces a HIGH severity regulatory risk environment. All 4 constituents noted regulatory impacts. THEMISMED is experiencing active disruption in a major line of business, stating the matter is under review with regulators. INDSWFTLAB highlighted rising global regulatory scrutiny from agencies like MHRA and TGA, while SENORES must maintain compliance for its newly acquired Apnar facility. commodity risk is a MEDIUM severity headwind; 506414 recorded an INR 2.0 crore reversal due to slow-moving semi-finished inventory in its animal nutrition segment. Finally, labor risk emerged as a LOW severity factor, with 506414 booking a one-time exceptional expense of INR 2.19 crore due to the notification of new Labour Codes.

Bottom Line

The sector is navigating a transition phase where Operating Leverage Inflection and Value Added Product Mix Shift are driving bottom-line outperformance even when top-line growth is uneven. Companies with clean regulatory records and expanding ANDA portfolios, like SENORES, are capturing outsized gains. Conversely, entities facing regulatory reviews or commodity inventory issues are lagging. The overarching trajectory remains positive, provided companies can successfully manage the heightened global regulatory scrutiny.